Metabolic benefits of inhibiting cAMP-PDEs with resveratrol
- PMID: 23700542
- PMCID: PMC3609109
- DOI: 10.4161/adip.21158
Metabolic benefits of inhibiting cAMP-PDEs with resveratrol
Abstract
Calorie restriction (CR) extends lifespan in species ranging from yeast to mammals. There is evidence that CR also protects against aging-related diseases in non-human primates. This has led to an intense interest in the development of CR-mimetics to harness the beneficial effects of CR to treat aging-related diseases. One CR-mimetic that has received a great deal of attention is resveratrol. Resveratrol extends the lifespan of obese mice and protects against obesity-related diseases such as type 2 diabetes. The specific mechanism of resveratrol action has been difficult to elucidate because resveratrol has a promiscuous target profile. A recent finding indicates that the metabolic effects of resveratrol may result from competitive inhibition of cAMP-degrading phosphodiesterases (PDEs), which increases cAMP levels. The cAMP-dependent pathways activate AMP-activated protein kinase (AMPK), which is essential for the metabolic effects of resveratrol. Inhibiting PDE4 with rolipram reproduces all of the metabolic benefits of resveratrol, including protection against diet-induced obesity and an increase in mitochondrial function, physical stamina and glucose tolerance in mice. This discovery suggests that PDE inhibitors may be useful for treating metabolic diseases associated with aging.
Keywords: AMP-activated protein kinase; Epac1; Sirt1; aging; cAMP; calorie-restriction; metabolic; phosphodiesterases; resveratrol.
Comment on
- Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148:421–33. doi: 10.1016/j.cell.2012.01.017.
Similar articles
-
Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases.Cell. 2012 Feb 3;148(3):421-33. doi: 10.1016/j.cell.2012.01.017. Cell. 2012. PMID: 22304913 Free PMC article.
-
Resveratrol as a calorie restriction mimetic: therapeutic implications.Trends Cell Biol. 2012 Oct;22(10):546-54. doi: 10.1016/j.tcb.2012.07.004. Epub 2012 Aug 10. Trends Cell Biol. 2012. PMID: 22885100 Free PMC article. Review.
-
Resveratrol provides neuroprotection by inhibiting phosphodiesterases and regulating the cAMP/AMPK/SIRT1 pathway after stroke in rats.Brain Res Bull. 2016 Mar;121:255-62. doi: 10.1016/j.brainresbull.2016.02.011. Epub 2016 Feb 11. Brain Res Bull. 2016. PMID: 26876758
-
Mitochondrial biogenesis: pharmacological approaches.Curr Pharm Des. 2014;20(35):5507-9. doi: 10.2174/138161282035140911142118. Curr Pharm Des. 2014. PMID: 24606795
-
Calorie restriction and dietary restriction mimetics: a strategy for improving healthy aging and longevity.Curr Pharm Des. 2014;20(18):2950-77. doi: 10.2174/13816128113196660699. Curr Pharm Des. 2014. PMID: 24079773 Review.
Cited by
-
The protective effect of the PDE-4 inhibitor rolipram on intracerebral haemorrhage is associated with the cAMP/AMPK/SIRT1 pathway.Sci Rep. 2021 Oct 5;11(1):19737. doi: 10.1038/s41598-021-98743-w. Sci Rep. 2021. PMID: 34611179 Free PMC article.
-
Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.Front Behav Neurosci. 2016 Jun 30;10:136. doi: 10.3389/fnbeh.2016.00136. eCollection 2016. Front Behav Neurosci. 2016. PMID: 27445731 Free PMC article.
-
Resveratrol Modulates the Gut-Brain Axis: Focus on Glucagon-Like Peptide-1, 5-HT, and Gut Microbiota.Front Aging Neurosci. 2020 Nov 24;12:588044. doi: 10.3389/fnagi.2020.588044. eCollection 2020. Front Aging Neurosci. 2020. PMID: 33328965 Free PMC article. Review.
-
Potent PDE4 inhibitor activates AMPK and Sirt1 to induce mitochondrial biogenesis.PLoS One. 2021 Jun 17;16(6):e0253269. doi: 10.1371/journal.pone.0253269. eCollection 2021. PLoS One. 2021. PMID: 34138962 Free PMC article.
-
Phosphodiesterase-4 Inhibitor Roflumilast-Mediated Protective Effect in Sepsis-Induced Late-Phase Event of Acute Kidney Injury: A Narrative Review.Pharmaceuticals (Basel). 2022 Jul 20;15(7):899. doi: 10.3390/ph15070899. Pharmaceuticals (Basel). 2022. PMID: 35890197 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources